Despite Challenges, Congestive Heart Failure Draws A Crowd
This article was originally published in The Pink Sheet Daily
Executive Summary
Biopharma companies are drawn to CHF, despite the lack of effective biomarkers and the need for large, expensive trials.
You may also be interested in...
Merck R&D: A Jam-Packed Pipeline But Much Of It Wait-And-See
Following the acquisition of Schering-Plough, Merck has one of the most robust pipelines in the industry, but after an R&D day May 11, much of the most interesting data is still yet to be seen.
Novartis Offers $120 Million For Corthera Eyeing Phase III Acute Cardiology Product
Relaxin enables the pharma to expand its reach in acute cardiology as its mega-drug Diovan faces patent expiries.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.